Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target boosted by equities research analysts at Piper Sandler from $854.00 to $865.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price objective would indicate a potential upside of 10.69% from the stock’s current price.
A number of other analysts have also recently weighed in on REGN. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the company from $660.00 to $978.00 in a report on Thursday. Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Robert W. Baird raised their price objective on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a research note on Friday, July 31st. Finally, Truist Financial raised their price objective on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $845.59.
Read Our Latest Stock Analysis on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Price Performance
Shares of NASDAQ:REGN traded down $9.26 during trading hours on Monday, hitting $781.48. 140,530 shares of the company’s stock traded hands, compared to its average volume of 818,103. Regeneron Pharmaceuticals has a 52 week low of $572.75 and a 52 week high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company’s fifty day simple moving average is $791.72 and its two-hundred day simple moving average is $721.59. The company has a market cap of $80.46 billion, a price-to-earnings ratio of 19.34, a price-to-earnings-growth ratio of 1.37 and a beta of 0.16.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the firm earned $12.81 EPS. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals will post 47.93 EPS for the current fiscal year.
Insider Activity
In other news, Director Huda Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the business. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth $26,000. Armstrong Advisory Group Inc. increased its holdings in Regeneron Pharmaceuticals by 466.7% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 28 shares during the period. Trust Co. of Vermont bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $29,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.
Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.
Further Reading
- Five stocks we like better than Regeneron Pharmaceuticals
- Illinois Tool Works Faces Headwinds—2 Alternatives Stand Out
- Luxury’s Middle Market Is Cracking—These 3 Stocks Could Win
- Rate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are Diverging
- The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
